Week in Review: Fosun Pharma to Spend $300 Million from Hong Kong IPO on M&A
Fosun Pharma expects tor raise $600 million in its upcoming Hong Kong IPO and will spend half of it on deals; Medtronic will pay $66 million to purchase a 26% stake in LifeTech Scientific, a Shenzhen cardiovascular medical device maker; Shenzhen Hepalink Pharma entered $21 million of deals with ProMetic Life Sciences of Canada; Legend Capital, a China PE/VC investment firm, believes innovative companies in China's medical device sector will become major entities; TNI BioTech of the US out-licensed the China rights for two R&D-stage cancer treatments to Hubei Qianjiang Pharma; Pharmaron, China’s third-largest CRO, announced a multi-year drug discovery partnership with AstraZeneca; WuXi AppTech officially opened its GMP manufacturing facility for biologic drugs, the first one in China compliant with US, EU and China standards; Shanghai has established an institute for advanced mAB studies and named a US researcher as director; and Complete Genomics, the California sequencing company, gained a partial victory in Illumina’s patent suit against Complete. More details…. Stock Symbols: (SHA: 600196) (NYSE: MDT) (HK: 8122) (SHE: 002399) (TSX: PLI) (PINKSHEETS: TNIB) (SHA: 600568) (NYSE: AZN) (NYSE: WX) (NSDQ: GNOM) (NSDQ: ILMN) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here